AMGN vs. NTRA: Amgen vs. Natera Stock Comparison

Company Profile

Amgen (AMGN) and Natera (NTRA) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Natera (NTRA) has an aggressive beta of 1.58, indicating higher sensitivity to broad-market moves, while Amgen (AMGN) is defensive at 0.43 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Natera (NTRA) reports a negative ROE of -10.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Amgen (AMGN) reports 78.35%, ranking against industry peers normally.

Natera (NTRA) reports a negative net margin of -5.66%, usually indicating a net loss over the period. Meanwhile Amgen (AMGN) reports 24.14%, ranking against industry peers normally.

Natera (NTRA) reports a negative operating margin of -7.64%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Amgen (AMGN) reports 35.79%, ranking against industry peers normally.

Profitability Metrics

Growth

Both Amgen (AMGN) at 9.95% and Natera (NTRA) at 35.90% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Amgen (AMGN) reports EPS growth of 88.23%, ranked against its industry; Natera (NTRA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Natera (NTRA) at 2.81 keeps current ratio within its industry’s typical mid-range, while Amgen (AMGN) at 1.48 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AMGN.

Natera (NTRA) at 0.13 is near its industry mid-range for debt-to-equity ratio, while Amgen (AMGN) at 3.76 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Natera (NTRA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a yield of 2.16%, ranking against industry peers normally.

Natera (NTRA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a payout of 57.62%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Amgen (AMGN) trades at 26.69 times trailing earnings, ranked against its peers, while Natera (NTRA) has no P/E ratio this period.

On P/S ratio, both Amgen (AMGN) at 6.40 and Natera (NTRA) at 15.49 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Measured against book value, both Amgen (AMGN) at 17.35 and Natera (NTRA) at 23.99 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics